Stryker Corporation · NYSE (us_market)
Healthcare · Medical Devices · United States
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-01-27$399.90 RISE2025-04-08$337.37 PEAK2025-07-01$396.74 155d | -15.6% 71d | Missed | Missed | — | — | +17.6% 84d | Missed |
DROP2023-06-30$305.09 RISE2023-10-12$253.85 PEAK2024-01-09$303.25 193d | -16.8% 104d | Missed | Missed | — | — | +19.5% 89d | Missed |
DROP2022-04-20$276.37 RISE2022-07-18$189.27 PEAK2022-09-12$231.83 145d | -31.5% 89d | Missed | Missed | — | — | +22.5% 56d | Missed |
DROP2021-09-08$280.09 RISE2021-11-30$236.63 PEAK2022-01-04$277.77 118d | -15.5% 83d | Missed | Missed | — | — | +17.4% 35d | Missed |
DROP2020-02-19$225.10 RISE2020-06-26$173.76 PEAK2020-09-16$215.81 210d | -22.8% 128d | Missed | Missed | — | — | +24.2% 82d | Missed |
DROP2020-02-19$225.10 RISE2020-03-23$126.50 PEAK2020-06-05$207.03 107d | -43.8% 33d | Missed | Missed | — | — | +63.7% 74d | Missed |
Globus Medical is shifting robotics deals to leases and rentals, aiming to expand its installed base and build recurring revenue streams.
Stryker recently launched its Pangea Plating System in Europe, a surgeon‑collaborated trauma platform designed to stabilize a wide range of fracture patterns across upper and lower extremities. The system’s use of global anatomical data and variable‑angle plating underscores Stryker’s push to tailor fracture fixation solutions to diverse patient populations and surgeon preferences. Next, we’ll explore how this European Pangea launch, alongside recent cyberattack disclosures, could influence...
Stryker (SYK) is back in focus after mixed first quarter results, a disruptive cyberattack, and a series of analyst updates, even as the company rolls out new products and reorganizes parts of its business. See our latest analysis for Stryker. At a share price of US$307.63, Stryker’s short term share price return has been weak, with the stock down 20.6% over the past 90 days. The 5 year total shareholder return of 29.73% points to longer term gains and suggests recent momentum has faded as...
Globus Medical's Q1 showed margin gains, strong spine and trauma growth, and rising robotics adoption as NuVasive synergies support 2026 targets.
Stryker Corporation (NYSE:SYK) is one of the best medical technology stocks to buy right now. On May 12, Argus analyst David Toung cut his price target on Stryker Corporation (NYSE:SYK) to $350 from $435 while keeping a Buy rating. This call followed a cyberattack that upended Stryker’s first quarter and sent its stock to a […]
Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.
SYK launches Pangea Plating System in Europe, completing its first London case as it broadens trauma care solutions for many fractures.
April net investment activity reached a multi-year low. Read what prompted a cautious approach and check out the dividend portfolio here.
Stryker Corporation (NYSE:SYK) is one of the best robotic surgery stocks to buy. Barclays cut the price target on Stryker Corporation (NYSE:SYK) to $394 from $469 on May 4, maintaining an Overweight rating on the shares. The firm told investors in a research note that the company’s fiscal Q1 results were mixed and below the […]
Stryker Corporation (NYSE:SYK) is one of the best robotic surgery stocks to buy. Barclays cut the price target on Stryker Corporation (NYSE:SYK) to $394 from $469 on May 4, maintaining an Overweight rating on the shares. The firm told investors in a research note that the company’s fiscal Q1 results were mixed and below the […]
AMSTERDAM, May 26, 2026--Stryker announced the European launch of its Pangea Plating System, a plating platform for the treatment of a wide range of fracture patterns.
Stryker (NYSE:SYK) has agreed to acquire Amplitude Vascular Systems. The deal adds hydraulic intravascular lithotripsy technology aimed at treating calcified peripheral arterial disease. The transaction is intended to expand Stryker's peripheral vascular portfolio and support its medical technology focus. Stryker, trading at around $313.5, is using this acquisition to build out its peripheral vascular offerings at a time when calcified peripheral arterial disease remains a difficult area of...
Stryker (NYSE:SYK) has agreed to acquire Amplitude Vascular Systems. The deal adds hydraulic intravascular lithotripsy technology aimed at treating calcified peripheral arterial disease. The transaction is intended to expand Stryker's peripheral vascular portfolio and support its medical technology focus. Stryker, trading at around $313.5, is using this acquisition to build out its peripheral vascular offerings at a time when calcified peripheral arterial disease remains a difficult area of...
William Berry Jr. will retire in September, with Corporate Controller Emily Baculik stepping into the role.
William Berry Jr. will retire in September, with Corporate Controller Emily Baculik stepping into the role.
The healthcare team covers Q1 results from pharma and medtech companies and provides a wrap-up of the key takeaways.
The healthcare team covers Q1 results from pharma and medtech companies and provides a wrap-up of the key takeaways.
Stryker stock has underperformed the broader market over the past year, but analysts remain highly bullish about its prospects.
Stryker's integrated 'Smart Hospital' strategy deepens customer lock-in, creating high switching costs and stable long-term demand. See why SYK stock is a Hold.
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| SYK | +3.52% | -21.17% | -13.20% | -20.27% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +0.55% | -15.45% | -9.75% | -32.96% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 15.35M | $5.06B | 0.17% | Added+0.6% | 2026-03-31 |
| Wellington | fundamental | 8.12M | $2.67B | 0.50% | Added+25.1% | 2026-03-31 |
| CapResearch | fundamental | 5.61M | $1.84B | 0.29% | Trimmed-5.9% | 2026-03-31 |
| FidelityFMR | fundamental | 2.36M | $776.92M | 0.04% | Trimmed-20.7% | 2026-03-31 |
| DEShaw | quant | 600.8K | $197.41M | 0.12% | Added+22.9% | 2026-03-31 |
| TwoSigma | quant | 469.2K | $154.18M | 0.12% | Added+427.0% | 2026-03-31 |
| RenTech | quant | 391.6K | $128.68M | 0.20% | Trimmed-3.6% | 2026-03-31 |
| Bridgewater | macro | 26.4K | $8.68M | 0.04% | Trimmed-20.0% | 2026-03-31 |
| Citadel | multi-strat | 25.2K | $8.29M | 0.01% | New | 2026-03-31 |
| TRowePrice | fundamental | 10.04M | $3.30M | 0.38% | Trimmed-0.8% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-29 | Fletcher Robert S | VP, Chief Legal Officer | S Open-market sale | 125 | $310.22 | −$38.8K |
| 2026-05-29 | Fletcher Robert S | VP, Chief Legal Officer | S Open-market sale | 258 | $308.79 | −$79.7K |
| 2026-05-29 | Fletcher Robert S | VP, Chief Legal Officer | S Open-market sale | 1,067 | $307.30 | −$327.9K |
| 2026-05-29 | Fletcher Robert S | VP, Chief Legal Officer | S Open-market sale | 2,809 | $306.56 | −$861.1K |
| 2026-05-29 | Fletcher Robert S | VP, Chief Legal Officer | S Open-market sale | 165 | $305.66 | −$50.4K |
| 2026-05-29 | Fletcher Robert S | VP, Chief Legal Officer | S Open-market sale | 120 | $304.23 | −$36.5K |
| 2026-05-28 | STRYKER RONDA E | Director | S Open-market sale | 3,707 | $315.11 | −$1.17M |
| 2026-05-28 | STRYKER RONDA E | Director | S Open-market sale | 10,407 | $314.38 | −$3.27M |
| 2026-05-28 | STRYKER RONDA E | Director | S Open-market sale | 44,060 | $313.35 | −$13.81M |
| 2026-05-28 | STRYKER RONDA E | Director | S Open-market sale | 114,059 | $312.44 | −$35.64M |
| 2026-05-28 | STRYKER RONDA E | Director | S Open-market sale | 115,960 | $311.60 | −$36.13M |
| 2026-05-28 | STRYKER RONDA E | Director | S Open-market sale | 21,807 | $310.77 | −$6.78M |
| 2026-05-12 | Fink M Kathryn | VP, Chief HR Officer | M Option exercise(deriv) | 11,850 | — | +$0 |
| 2026-05-12 | Fink M Kathryn | VP, Chief HR Officer | M Option exercise(deriv) | 9,732 | — | +$0 |
| 2026-05-12 | Fink M Kathryn | VP, Chief HR Officer | S Open-market sale | 3,500 | $283.45 | −$992.1K |
| 2026-05-12 | Fink M Kathryn | VP, Chief HR Officer | S Open-market sale | 5,220 | $283.85 | −$1.48M |
| 2026-05-12 | Fink M Kathryn | VP, Chief HR Officer | F Tax withholding | 16,362 | $294.23 | −$4.81M |
| 2026-05-12 | Fink M Kathryn | VP, Chief HR Officer | M Option exercise | 11,850 | $179.35 | +$2.13M |
| 2026-05-12 | Fink M Kathryn | VP, Chief HR Officer | M Option exercise | 9,732 | $154.14 | +$1.50M |
| 2026-05-08 | King Debra | See Remarks | A Grant / award | 1,016 | — | +$0 |
| 2026-05-08 | Montagnino Kimberly Ann | VP, Chief Comm. Officer | A Grant / award | 677 | — | +$0 |
| 2026-05-08 | BRAINERD MARY K | Director | A Grant / award | 762 | — | +$0 |
| 2026-05-08 | Caforio Giovanni | Director | A Grant / award | 762 | — | +$0 |
| 2026-05-08 | Maceda Emmanuel Perez | Director | A Grant / award | 762 | — | +$0 |
| 2026-05-08 | McCoy Sherilyn S | Director | A Grant / award | 762 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-30upcoming | 3.48 | — | — |
| 2026-04-30 | 2.98 | 2.60 | -12.86% |
| 2026-01-29 | 4.40 | 4.47 | +1.70% |
| 2025-10-30 | 3.13 | 3.19 | +1.87% |
| 2025-07-31 | 3.07 | 3.13 | +1.95% |
| 2025-05-01 | 2.28 | 1.69 | -25.83% |
| 2025-01-28 | 3.87 | 4.01 | +3.49% |
| 2024-10-29 | 2.77 | 2.87 | +3.49% |
| 2024-07-30 | 2.79 | 2.81 | +0.68% |
| 2024-04-30 | 2.36 | 2.50 | +6.12% |
| 2024-01-30 | 3.27 | 3.46 | +5.88% |
| 2023-11-02 | 2.44 | 2.46 | +0.92% |
| 2023-08-03 | 2.38 | 2.54 | +6.80% |
| 2023-05-01 | 2.00 | 2.14 | +6.86% |
| 2023-01-31 | 2.84 | 3.00 | +5.81% |
| 2022-10-31 | 2.23 | 2.12 | -4.85% |